Strattera (atomoxetine) was the first non-stimulant approved for ADHD in the United States, in 2002. It's still the most-prescribed non-stimulant. But it works very differently from Adderall or Ritalin, and patients who expect a stimulant-like response are often disappointed in the first weeks. Understanding what it does and how it builds up over time changes the expectations.

What it does at the neuron level

Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). When a neuron releases norepinephrine into the synapse, that neurotransmitter normally gets pulled back into the releasing neuron by transporters. Atomoxetine blocks those norepinephrine transporters (NET), so norepinephrine stays in the synapse longer and signals more.

In the prefrontal cortex specifically, NET also helps clear dopamine (because there are relatively few dedicated dopamine transporters in that region). So atomoxetine indirectly raises both norepinephrine and dopamine in the prefrontal cortex — but only there.

This is the key difference from stimulants: stimulants raise dopamine throughout the brain, including in striatal reward pathways. Atomoxetine doesn't. That's why it doesn't produce the quick "I feel it kick in" sensation, doesn't have abuse potential, and isn't a controlled substance.

Why it takes weeks

Stimulants work on absorbing-and-binding timescales — minutes to hours. Atomoxetine works on a different mechanism. The pharmacological effect of blocking NET is immediate, but the clinical effect on ADHD symptoms builds gradually as neuroadaptive changes occur in noradrenergic signaling. This is similar to how SSRIs take 4–6 weeks for clinical effect on depression even though they start blocking serotonin reuptake immediately.

Most clinicians evaluate atomoxetine response at:

Week 1–2: tolerability check. Side effects (nausea, sleepiness, decreased appetite) are most prominent here. Usually not the time to judge whether it's working.
Week 4: early efficacy check. Some early signal but not the full effect.
Week 8–12: full efficacy assessment. This is when most clinicians decide whether to continue, increase, or switch.

Stopping atomoxetine before 6–8 weeks is one of the most common reasons people conclude "it didn't work" — when in many cases it just hadn't reached steady-state effect yet.

Who benefits most

Atomoxetine tends to be a better fit when one or more of the following apply:

Stimulants caused intolerable side effects — significant anxiety, jitteriness, mood lability, sleep disruption, or appetite issues.
History of stimulant misuse or substance use disorder concerns.
Comorbid anxiety — stimulants can sometimes worsen anxiety; atomoxetine often doesn't.
Tic disorder — stimulants can sometimes unmask or worsen tics; atomoxetine doesn't.
Steady, all-day coverage preferred over the typical 8–12-hour stimulant window.
Cardiovascular concerns that limit stimulant use — though atomoxetine still has its own cardiovascular profile to consider.

What to expect on it

Common adjustments and patterns:

Take with food to reduce nausea, especially in the first 1–2 weeks.
Start at a low dose (40 mg in adults; weight-based in kids) and titrate up after a week. Most people end up at 80 mg/day for adults; the FDA-approved max is 100 mg/day.
Effect is steady-state — there's no peak/trough, no crash, no morning vs. afternoon difference. Some patients describe it as feeling like "nothing happened" until they look back at week 6 and realize they're getting more done than they used to.
If you're a CYP2D6 poor metabolizer (common in some populations), the half-life is much longer (~24 hours) and side effects can be more pronounced. Pharmacogenomic testing is sometimes useful.

Important warnings

Boxed warning: increased suicidal ideation in pediatric patients during early treatment. Monitor closely.
Rare but serious hepatotoxicity — discontinue immediately if jaundice, dark urine, or unusual fatigue occurs.
Caution with narrow-angle glaucoma, cardiovascular conditions, and certain drug interactions (especially MAOIs and strong CYP2D6 inhibitors).

Atomoxetine isn't right for everyone, and it isn't usually as immediately impactful as a well-titrated stimulant. But for the right patient, it provides steady, all-day improvement in attention without the rollercoaster shape, and without the abuse profile.

See the full reference for atomoxetine on its medication detail page, or compare it side-by-side with stimulants in the comparison tool.